# XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

> **NCT00127933** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 157 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** capecitabine [Xeloda]
- **DRUG:** Taxotere
- **DRUG:** Herceptin (HER2-neu positive patients only)
- **DRUG:** capecitabine [Xeloda]
- **DRUG:** Taxotere

## Key facts

- **NCT ID:** NCT00127933
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-04
- **Final completion:** 2009-07
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2011-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00127933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00127933, "XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00127933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*